A Senate committee has progressed Dr. Erica Schwartz’s nomination to lead the Centers for Disease Control and Prevention (CDC), despite initial worries about her autonomy from political influence. If confirmed by the Senate, the 54-year-old would be the 22nd director of the CDC, responsible for safeguarding Americans against preventable health threats. Schwartz’s qualifications include degrees in medicine and law, experience as deputy surgeon general, and a leadership role in the U.S. Coast Guard.
Schwartz faced skepticism during a Senate Health, Education, Labor and Pensions Committee hearing. Chairman Sen. Bill Cassidy, a Republican from Louisiana, and others questioned whether she would resist directives from President Trump’s health secretary, Robert F. Kennedy Jr., if those directives contradicted scientific evidence and public health standards. Cassidy later expressed confidence in Schwartz after speaking with her and her associates, indicating his support was key for her nomination’s advancement.
The committee’s vote was nearly divided along party lines. Among the opponents was Sen. Bernie Sanders, an independent from Vermont, who emphasized the need for officials with the courage to oppose anti-science and conspiracy theories in the Trump administration.
Since Trump resumed office last year, the CDC has suffered from disorganization, with over 3,000 employees lost and morale declining. Political appointees lacking medical or public health expertise have filled the CDC’s front office.
Public health experts hope Schwartz can stabilize the CDC due to her credentials, especially since she was chosen by Trump and not Kennedy, an anti-vaccine advocate. Kennedy has tried to revise vaccine recommendations for children, although federal court actions have stalled some efforts. Kennedy’s approach initially concerned Cassidy, who ultimately supported Kennedy following assurances about maintaining current vaccine recommendations.
During her hearing, Schwartz was asked how she would handle instructions from political appointees that lacked scientific backing. She vowed not to betray science but hesitated to criticize some of Kennedy’s actions. The National Public Health Coalition, an organization involving former and current CDC employees, urged senators to secure clear commitments from Schwartz on safeguarding scientific independence and evidence-based vaccine policy.
The coalition noted that Schwartz’s responses were often unclear or inadequate. She did not commit to removing a CDC webpage incorrectly suggesting a vaccine-autism link. Modifications have been made as a gesture of goodwill, yet the page still challenges evidence-based vaccine claims. Dr. Georges Benjamin of the American Public Health Association interpreted Schwartz’s answers as balancing conflicting pressures. Despite some disagreements, he supports her nomination given her potential to rebuild the CDC’s leadership and restore public trust through shared priorities like addressing foodborne diseases.
Former CDC official Dr. Daniel Jernigan stressed the importance of Schwartz’s confirmation to end the agency’s leadership vacuum. Kennedy, however, might prefer her rejection to continue his anti-science initiatives unchallenged.
Schwartz is the third nominee for the post within 18 months. Previous candidates included Dr. David Weldon, withdrawn due to insufficient Senate support, and Susan Monarez, briefly confirmed before her removal for not aligning with Trump’s agenda. Leadership vacancies extend beyond the CDC, with positions like surgeon general and FDA commissioner also unfilled. Sean Kaufman’s nomination for assistant health secretary was approved, despite his controversial views on vaccines. Cassidy emphasized that Kaufman would not influence vaccine policy directly. Sanders criticized Kaufman’s nomination, urging better choices from the Trump administration.